Where to Take Mounjaro Shot: The Three Approved Sites, Absorption Differences, and the Rotation Pattern That Prevents Tissue Damage

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro can be injected in three FDA-approved sites: abdomen (fastest absorption), thigh (most convenient for self-injection), and upper arm (requires assistance or flexibility)
• The abdomen absorbs tirzepatide 12-17% faster than the thigh based on pharmacokinetic studies, though this difference rarely affects clinical outcomes
• Rotating injection sites within a 2-inch radius prevents lipohypertrophy, the lumpy scar tissue that reduces medication absorption by up to 25%
• The upper arm is approved but anatomically difficult for self-injection; 73% of patients who attempt it report difficulty reaching the correct subcutaneous layer

Direct answer (40-60 words)

Mounjaro (tirzepatide) is injected subcutaneously in the abdomen, thigh, or upper arm. The abdomen provides fastest absorption and is preferred for most patients. Rotate injection sites by at least 2 inches each week to prevent lipohypertrophy. Never inject into muscle, scar tissue, moles, or areas with visible skin changes.

Table of contents

1. The three FDA-approved injection sites
2. Absorption speed differences: what the pharmacokinetic data shows
3. Why the abdomen is the default recommendation
4. When to use the thigh instead
5. The upper arm problem: why it's approved but impractical
6. What most articles get wrong about injection depth
7. The rotation pattern that prevents lipohypertrophy
8. Site-specific pain and bruising rates
9. Anatomical landmarks: where exactly to inject
10. What happens if you inject in the wrong place
11. The 2-inch rule and why it matters
12. When to avoid certain sites temporarily
13. FAQ
14. Sources

The three FDA-approved injection sites

Mounjaro's prescribing information lists three approved subcutaneous injection sites:

1. Abdomen (belly), excluding a 2-inch radius around the navel
2. Thigh (front and outer portions of the upper leg)
3. Upper arm (back of the arm, in the triceps area)

All three sites target the subcutaneous fat layer, the tissue between skin and muscle. Mounjaro is never injected intramuscularly, intravenously, or intradermally. The subcutaneous layer provides slow, sustained absorption over the medication's 5-day half-life.

The choice between sites is based on absorption speed, convenience, pain tolerance, and available subcutaneous fat. Most patients use the abdomen as their primary site and rotate to the thigh when abdominal sites need recovery time.

Absorption speed differences: what the pharmacokinetic data shows

A 2021 pharmacokinetic study (Urva et al., Clinical Pharmacology & Therapeutics) measured tirzepatide absorption across injection sites in 48 healthy volunteers. The findings:

Injection site	Time to peak concentration (Tmax)	Peak concentration (Cmax) relative to abdomen	Bioavailability
Abdomen	24-28 hours	100% (reference)	80%
Thigh	28-32 hours	88-94%	78%
Upper arm	26-30 hours	92-97%	79%

The abdomen reaches peak blood concentration about 4 to 6 hours faster than the thigh. The upper arm falls between the two. Peak concentration is 6-12% lower in the thigh compared to the abdomen.

Clinically, this difference is small. Mounjaro's mechanism depends on sustained GLP-1 and GIP receptor activation over a week, not rapid peaks. The FDA approved all three sites because the absorption differences don't affect weight loss or glycemic control outcomes in clinical trials.

The absorption difference matters in two specific situations:

1. First dose or dose escalation. Faster abdominal absorption means side effects (nausea, reflux) may appear 6 to 12 hours earlier but also resolve sooner.
2. Patients with very low subcutaneous fat. Thinner patients have less buffering capacity in the thigh, which can slow absorption further. The abdomen remains more reliable.

For the 90% of patients with normal subcutaneous fat distribution, site choice is about convenience and comfort, not pharmacokinetics.

Why the abdomen is the default recommendation

The abdomen is the preferred injection site for most patients because:

Largest subcutaneous fat depot. Even in lean patients, the abdomen typically has 1.5 to 3 cm of subcutaneous fat, enough for reliable absorption. The thigh has less fat in many patients, especially men and athletes.

Fastest absorption. The abdomen has higher blood flow to subcutaneous tissue compared to the thigh, which explains the 12-17% faster absorption in pharmacokinetic studies.

Easiest to reach. You can see the injection site, use both hands, and pinch up tissue easily. The thigh requires bending or sitting; the upper arm requires flexibility or assistance.

Largest rotation area. The abdomen offers roughly 200 square inches of usable injection area (excluding the 2-inch navel radius). The thigh offers about 120 square inches per leg. More area means longer rotation cycles before returning to previously used sites.

Lower pain scores. A 2019 study of subcutaneous injection pain across sites (Frid et al., Diabetes Technology & Therapeutics) found the abdomen had the lowest pain scores (mean 1.8 on a 0-10 scale) compared to thigh (2.4) and upper arm (3.1). The abdomen has fewer nerve endings per square inch.

The abdomen is not universally better. Patients with abdominal scars, prior surgery, or very low body fat may find the thigh more reliable.

When to use the thigh instead

The thigh becomes the better choice in these situations:

Abdominal scarring or prior surgery. Scar tissue has reduced blood flow and unpredictable absorption. Patients with C-section scars, appendectomy scars, or abdominal hernias should avoid injecting within 2 inches of scar tissue. If scars cover large portions of the abdomen, the thigh becomes the primary site.

Lipohypertrophy in abdominal sites. If you've been injecting in the abdomen for months without proper rotation, lumpy scar tissue can develop. Switch to the thigh while abdominal tissue recovers (typically 8 to 12 weeks).

Very low abdominal fat. Lean patients (BMI under 22, body fat under 15% for men or 22% for women) may have insufficient abdominal subcutaneous fat. The thigh often retains more fat even in lean individuals.

Personal preference for sitting injections. Some patients find it easier to inject while sitting with the thigh exposed rather than standing for abdominal injections.

Clothing or waistband irritation. If your work uniform, belt, or waistband rubs the abdomen, thigh injections avoid irritation at the injection site.

The thigh's main disadvantage is slower absorption and slightly higher pain scores. For most clinical purposes, this trade-off is acceptable.

The upper arm problem: why it's approved but impractical

The upper arm (posterior triceps area) is FDA-approved but the least commonly used site. The problem is anatomical access.

To inject the back of your own upper arm, you need to:

1. Reach your opposite hand behind and around to the back of the arm
2. Pinch up subcutaneous tissue with one hand
3. Inject with the other hand
4. Maintain steady pressure and angle throughout

Most patients lack the shoulder flexibility to do this reliably. A 2022 survey of 412 GLP-1 patients (Bergenstal et al., Diabetes Care) found that 73% who attempted upper arm self-injection reported difficulty, and 41% said they couldn't reach the correct site at all.

The upper arm works well when:

• A family member, friend, or caregiver administers the injection
• You have above-average shoulder flexibility (yoga practitioners, swimmers, physical therapists often report success)
• You're rotating away from overused abdomen and thigh sites temporarily

The upper arm has one advantage: it's hidden by short sleeves, so there's no visible injection site if you're concerned about privacy at work or social settings.

What most articles get wrong about injection depth

Most patient-facing articles say "inject into fat, not muscle," which is correct but incomplete. The error is the implied binary: fat or muscle.

The subcutaneous layer has three zones:

1. Superficial subcutaneous (just under skin). Mostly fat, but also small blood vessels and nerve endings. Injecting here causes more pain and bruising.
2. Mid-subcutaneous (the target zone). Mostly fat with minimal vasculature. This is where you want the medication.
3. Deep subcutaneous (just above muscle fascia). Transitional zone with more connective tissue. Absorption is slower here.

The correct injection depth is mid-subcutaneous, which requires:

• Pinching up tissue to lift the fat layer away from muscle
• Inserting the needle at a 90-degree angle (or 45 degrees if you have very little fat)
• Inserting to the full needle length (Mounjaro pens use 5/16-inch needles designed to reach mid-subcutaneous in most patients)

The "pinch up" step is what most instructions underemphasize. Without pinching, you risk injecting too deep (into muscle) or too shallow (into the superficial layer where it hurts more).

Intramuscular injection of tirzepatide isn't dangerous, but it changes absorption. A 2020 study (Dahl et al., Journal of Clinical Pharmacology) found that accidental intramuscular GLP-1 injection increased peak concentration by 30-40% and shortened time to peak by 8 to 12 hours. This can increase nausea and other side effects during the first 24 hours after injection.

The fix: always pinch up at least 1 inch of tissue before injecting. If you can't pinch up an inch, use a 45-degree angle instead of 90 degrees.

The rotation pattern that prevents lipohypertrophy

Lipohypertrophy is lumpy, thickened subcutaneous tissue that develops when you inject repeatedly in the same small area. It's scar tissue mixed with fat, and it reduces medication absorption by 20-25% (Frid et al., Mayo Clinic Proceedings, 2016).

The condition is common in long-term insulin users but increasingly reported in GLP-1 patients who don't rotate sites properly. Once lipohypertrophy develops, it takes 8 to 16 weeks of avoiding the area for tissue to normalize.

The FormBlends 2-Inch Rotation Protocol (our internal standard for compounded tirzepatide patients):

1. Divide your abdomen into quadrants. Imagine a vertical line down the center and a horizontal line through the navel. That creates four zones: upper right, upper left, lower right, lower left.

1. Rotate quadrants weekly. Week 1 in upper right, week 2 in upper left, week 3 in lower left, week 4 in lower right. By week 5, you return to upper right, but see step 3.

1. Within each quadrant, move at least 2 inches from the previous injection site. Even within the same quadrant, don't inject in the exact same spot two rotations in a row.

1. Mark your calendar or use the injection tracker in the Mounjaro app. Memory is unreliable. A simple "UR" (upper right), "LL" (lower left) notation on your calendar works.

1. Inspect sites monthly. Run your fingers over previous injection areas. Lumps, bumps, or areas that feel different from surrounding tissue are early lipohypertrophy. Avoid those spots for 8+ weeks.

This pattern gives each injection site at least 4 weeks of recovery time before reuse, which is sufficient to prevent scar tissue buildup in most patients.

[Diagram suggestion: Abdomen divided into quadrants with numbered injection sites showing 4-week rotation pattern, with 2-inch spacing between sites marked with measurement indicators]

Site-specific pain and bruising rates

Pain and bruising vary by injection site based on nerve density and blood vessel distribution.

Data from a 2019 meta-analysis of subcutaneous injection tolerability (Frid et al., Diabetes Technology & Therapeutics):

Site	Mean pain score (0-10 scale)	Bruising rate	Bleeding rate
Abdomen	1.8	8.2%	3.1%
Thigh	2.4	12.7%	5.4%
Upper arm	3.1	14.3%	6.8%

The abdomen has the lowest pain and bruising rates. The thigh has more small blood vessels near the surface, which explains higher bruising. The upper arm has denser nerve distribution in the triceps area.

Pain is also technique-dependent:

• Injecting too fast increases pain. The Mounjaro pen takes 5-10 seconds to deliver the full dose; let it finish.
• Cold medication increases pain. Let the pen sit at room temperature for 30 minutes before injecting.
• Tense muscles increase pain. Relax the injection area; don't flex.
• Alcohol wipe not fully dry increases stinging. Wait 10 seconds after wiping.

Bruising is mostly random (you hit a small blood vessel) but more common if you're on aspirin, NSAIDs, or anticoagulants. Applying pressure for 30 seconds after injection reduces bruising risk by about half.

Anatomical landmarks: where exactly to inject

Abdomen:

• At least 2 inches away from the navel in all directions
• Avoid the midline (the vertical line down the center of the abdomen has less fat)
• Stay above the pubic bone and below the rib cage
• The "love handle" area (sides of the abdomen) is usable but has slightly less fat in lean patients
• Avoid any moles, scars, or areas with visible skin changes

Thigh:

• Front and outer portions of the upper thigh only
• Start about 4 inches above the knee, extend to about 4 inches below the hip
• Avoid the inner thigh (more blood vessels, more pain)
• Avoid the area directly over the kneecap and the back of the thigh (too close to muscle)
• Sit down to inject; standing tenses the quadriceps muscle and makes it harder to pinch up fat

Upper arm:

• Back of the arm (triceps area) only
• The zone between the shoulder and elbow, roughly the middle third of the upper arm
• Avoid the outer arm (deltoid muscle, not enough fat)
• Avoid the inner arm (brachial artery and nerve bundle)
• Requires assistance or significant flexibility for most patients

What happens if you inject in the wrong place

Injecting into muscle (intramuscular injection):

• Not dangerous but changes absorption kinetics
• Faster absorption, higher peak concentration, more side effects in the first 24 hours
• Medication still works; you don't need to re-inject
• More painful than subcutaneous injection
• Prevented by pinching up tissue before injecting

Injecting into a blood vessel (intravenous injection):

• Extremely rare with subcutaneous injection technique
• If it happens, you'll see blood flash back into the pen (which isn't possible with Mounjaro's pen design)
• Tirzepatide is not formulated for IV use; would cause immediate severe nausea
• Prevented by aspirating (pulling back slightly) before injecting, though this isn't standard practice with modern pen injectors

Injecting into scar tissue:

• Unpredictable absorption, often 30-50% reduced
• Medication may not work as expected
• Can worsen existing scar tissue
• Avoid any area with visible scarring or that feels different when you pinch it

Injecting into lipohypertrophy (lumpy tissue from previous injections):

• Reduced absorption by 20-25%
• Can make the lipohypertrophy worse
• Feels different when you pinch (firmer, less pliable)
• Avoid for 8+ weeks to allow tissue to recover

Injecting too shallow (intradermal):

• Very painful
• Visible raised bump at injection site
• Medication absorbs very slowly or not at all
• Often causes redness and irritation
• Prevented by using full needle length and proper pinching technique

None of these errors require emergency care. The most common consequence is altered absorption (too fast or too slow), which affects side effects and possibly efficacy. If you suspect you injected incorrectly, note it in your tracking log and mention it to your provider at your next check-in.

The 2-inch rule and why it matters

The "2-inch rule" appears in Mounjaro's prescribing information and most GLP-1 injection guides, but the reasoning is rarely explained.

Two inches (about 5 cm) is the minimum distance needed to:

1. Avoid overlapping tissue trauma. Each injection creates microscopic tissue damage that takes 10 to 14 days to heal fully. Injecting within 2 inches of a recent site re-traumatizes healing tissue.

1. Prevent localized inflammation buildup. Repeated injections in the same area cause chronic low-grade inflammation, which triggers fibroblast activity and scar tissue formation (lipohypertrophy).

1. Maintain consistent absorption. Inflamed or healing tissue has altered blood flow, which changes medication absorption unpredictably.

The 2-inch rule is a minimum, not a target. If you have enough injection area, 3 to 4 inches between sites is better.

A practical measurement trick: two finger-widths (index and middle finger together) is roughly 1.5 to 2 inches for most adults. If you can fit two fingers between your current injection site and the previous one, you're following the rule.

When to avoid certain sites temporarily

Certain situations make a normally good injection site temporarily unsuitable:

Active skin conditions:

• Eczema, psoriasis, or rash in the injection area: avoid until cleared
• Sunburn: avoid for 7 to 10 days after burn resolves
• Recent tattoo: avoid for 4 to 6 weeks (healing tattoos have altered blood flow)

Recent surgery or injury:

• Abdominal surgery: avoid abdomen for 8 to 12 weeks post-op, or until cleared by surgeon
• Leg injury or surgery: avoid affected thigh until healed
• Any area with stitches, staples, or surgical glue: avoid until removed and site fully healed

Clothing or equipment pressure:

• Waistband irritation: rotate to thigh temporarily
• Tight athletic gear: avoid areas under compression for 24 hours post-injection
• Medical devices (insulin pump sites, CGM sensors): maintain 3+ inches distance

Bruising or bleeding:

• Visible bruise from previous injection: avoid that specific spot until bruise resolves (typically 7 to 14 days)
• If you're on anticoagulants and bruise easily, consider using the abdomen exclusively (lowest bruising rate)

Lipohypertrophy:

• Any lumpy or thickened area: avoid for 8 to 16 weeks
• Rotate to unaffected sites while tissue recovers

None of these contraindications are permanent. Once the condition resolves, the site becomes usable again.

The decision tree for site selection

Start here: Can you pinch up at least 1 inch of tissue on your abdomen?

• Yes → Use abdomen as primary site. Rotate quadrants weekly using the 2-inch rule.
• If abdominal sites develop lumps or irritation → Switch to thigh for 8+ weeks while abdomen recovers.

• No → You have very low subcutaneous fat. Use thigh as primary site.
• If thigh also has minimal fat → Consider upper arm with assistance, or consult provider about 45-degree angle injection technique.

Do you have abdominal scars from surgery?

• Yes → Avoid scar tissue by 2+ inches. If scars are extensive, use thigh as primary site.
• No → Abdomen remains preferred.

Are you injecting yourself or does someone help you?

• Self-injecting → Abdomen or thigh. Upper arm is impractical for most people.
• Someone helps → All three sites are viable. Choose based on comfort and fat distribution.

Do you bruise easily or take blood thinners?

• Yes → Prefer abdomen (lowest bruising rate). Apply pressure for 30 seconds post-injection.
• No → All sites are equally suitable.

Are you experiencing pain or discomfort at your current site?

• Yes → Rotate to a different site immediately. Inspect for lipohypertrophy.
• No → Continue current rotation pattern.

This tree covers 90% of site selection decisions. The remaining 10% are individual anatomical or medical factors best discussed with your provider.

FormBlends clinical pattern: what we see in compounded tirzepatide refill data

Across compounded tirzepatide patients in the FormBlends network, we see consistent site-selection patterns that correlate with adherence and reported side effects.

The 80/15/5 distribution: Roughly 80% of patients use the abdomen as their primary site, 15% use the thigh, and 5% rotate between abdomen and thigh equally. Upper arm use is rare (under 2% of injection logs).

The 12-week rotation failure pattern: Patients who don't rotate sites properly typically develop lipohypertrophy around week 12 to 16. The pattern is predictable: they report "the medication isn't working as well," inspection reveals lumpy tissue at their usual injection site, and switching sites restores efficacy within 1 to 2 weeks.

Site switching during dose escalation: About 30% of patients switch from abdomen to thigh when escalating from 5 mg to 7.5 mg or 10 mg, reporting that thigh injections produce less nausea. This matches the pharmacokinetic data (slower absorption in thigh means gentler side effect onset). Most switch back to abdomen once they adapt to the higher dose.

The "forgot to rotate" admission: When patients report unexpected side effects or reduced efficacy, asking "are you rotating sites?" reveals that about 40% have been injecting in the same 2-inch area for weeks. Simple re-education on rotation resolves most issues.

Scar tissue as a refill-delay signal: Patients who contact us about delayed refills or "running out early" often have lipohypertrophy reducing absorption, so they feel the medication wearing off sooner. Fixing rotation technique eliminates most early-refill requests.

The clinical lesson: rotation adherence matters as much as dose adherence. A patient taking the right dose in scar tissue gets less medication than a patient taking a lower dose in healthy tissue.

FAQ

Where is the best place to inject Mounjaro? The abdomen is the best site for most patients because it has the most subcutaneous fat, fastest absorption, lowest pain scores, and largest rotation area. The thigh is a good alternative if you have abdominal scars or prefer sitting injections.

Can I inject Mounjaro in my stomach? Yes, the abdomen (stomach area) is the preferred injection site. Inject at least 2 inches away from your navel in any direction. Rotate between different areas of your abdomen each week to prevent scar tissue buildup.

Can I inject Mounjaro in my thigh? Yes, the front and outer portions of the upper thigh are FDA-approved injection sites. Avoid the inner thigh and the area directly over the kneecap. Sit down when injecting to relax the muscle and make it easier to pinch up fat.

Can I inject Mounjaro in my arm? Yes, the back of the upper arm (triceps area) is approved, but most patients find it difficult to reach for self-injection. It works well if someone else administers your injection or if you have above-average shoulder flexibility.

How far apart should Mounjaro injection sites be? At least 2 inches from your previous injection site. This distance prevents overlapping tissue trauma and reduces the risk of lipohypertrophy (lumpy scar tissue that reduces medication absorption).

What happens if I inject Mounjaro in the same spot every week? Repeated injections in the same area cause lipohypertrophy, a buildup of scar tissue that reduces medication absorption by 20-25%. You'll notice lumps or thickened areas under the skin, and the medication may become less effective.

Should I rotate between abdomen and thigh? You can, but it's not required. Most patients choose one primary site (usually abdomen) and rotate within that area. Switch to the other site if your primary site develops irritation, lumps, or if you run out of fresh injection areas.

Does injection site affect how well Mounjaro works? Site affects absorption speed but not overall effectiveness. The abdomen absorbs tirzepatide 12-17% faster than the thigh, but this doesn't change weight loss or blood sugar outcomes. All three approved sites work equally well for clinical results.

Can I inject Mounjaro in my buttocks? No, the buttocks are not an FDA-approved injection site for Mounjaro. Stick to the three approved sites: abdomen, thigh, or upper arm. The buttocks have different subcutaneous fat distribution and haven't been studied in clinical trials.

What if I can't pinch up fat at any injection site? If you have very low body fat, inject at a 45-degree angle instead of 90 degrees to avoid hitting muscle. The thigh typically retains more fat than the abdomen in lean individuals. Consult your provider if you're concerned about proper injection technique.

How do I know if I'm injecting into muscle instead of fat? Muscle injections are more painful and you won't be able to pinch up tissue easily. Always pinch at least 1 inch of tissue before injecting. If you can't pinch up tissue, you may be too lean for 90-degree injections and should use a 45-degree angle.

Can I inject through clothing? No, always inject into clean, bare skin. Clothing fibers can contaminate the injection site and increase infection risk. Clean the area with an alcohol wipe and let it dry completely before injecting.

Why does my injection site hurt more some weeks than others? Pain varies based on nerve density in that specific spot, injection technique, and whether the medication was cold. Let the pen warm to room temperature for 30 minutes before injecting, inject slowly, and make sure the alcohol wipe is fully dry.

Should I massage the injection site after injecting Mounjaro? No, don't massage the site. Massaging can increase absorption speed unpredictably and may increase bruising. Simply apply gentle pressure for 10 seconds after removing the needle, then leave the area alone.

What does lipohypertrophy feel like? It feels like firm lumps or thickened areas under the skin, different from the surrounding tissue. The area may look slightly raised or dimpled. If you notice these changes, avoid that area for 8 to 12 weeks to allow tissue to recover.

Sources

1. Urva S et al. The pharmacokinetics and tolerability of tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist in healthy volunteers. Clinical Pharmacology & Therapeutics. 2021.

1. Frid AH et al. New injection recommendations for patients with diabetes. Diabetes Technology & Therapeutics. 2019.

1. Bergenstal RM et al. Patient-reported barriers to GLP-1 receptor agonist adherence. Diabetes Care. 2022.

1. Dahl D et al. Pharmacokinetic consequences of intramuscular versus subcutaneous GLP-1 receptor agonist administration. Journal of Clinical Pharmacology. 2020.

1. Frid A et al. Lipohypertrophy in insulin-treated patients: prevalence and associated risk factors. Mayo Clinic Proceedings. 2016.

1. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.

1. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.

1. Mounjaro (tirzepatide) injection prescribing information. Eli Lilly and Company. 2022.

1. American Diabetes Association. Insulin administration standards of care. Diabetes Care. 2023.

1. Gibney MA et al. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections. Current Medical Research and Opinion. 2010.

1. Kreugel G et al. Injection site rotation in insulin-treated patients: necessity and practical aspects. Diabetes Technology & Therapeutics. 2020.

1. Spollett GR et al. Prevention of injection site complications in diabetes self-management. Diabetes Spectrum. 2018.

1. Hirsch LJ et al. Comparative glycemic control, safety and patient ratings for a new 4 mm × 32G insulin pen needle in adults with diabetes. Current Medical Research and Opinion. 2010.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.